Primary immune thrombocytopenia (ITP) is a blood system disease mediated by autoimmune mechanism. Currently, the goal of treatment for primary ITP is to keep patients' peripheral platelet count at a safe level to prevent severe bleeding. Recently, avatrombopag and fostamatinib have been approved by the FDA for the treatment of primary ITP in adults, while new drugs such as rozanolixizumab, efgartigimod, PRTX-100, decitabine and atorvastatin have shown efficacy in early clinical trials. This review summarizes the current accepted therapies for the clinical treatment of primary ITP in adults, and briefly discuss the progress of new therapies.
题目: 原发免疫性血小板减少症的治疗进展.
摘要: 原发免疫性血小板减少症（ITP）是一种由自身免疫机制介导的血液系统疾病。当前，原发ITP的治疗目标是保证患者外周血小板数处于一个安全水平，以防止患者出现严重的出血症状。近两年，新型药物阿伐曲泊帕、福坦替尼已被美国食品药品监督管理局批准用于成人ITP的治疗，而rozanolixizumab、efgartigimod、PRTX-100、地西他滨以及阿托伐他汀等药物也在早期的临床试验中展现了一定的疗效。本篇综述将就当前用于成年原发ITP患者临床治疗的各类方法进行概述，并讨论近年来各新型疗法的研究进展.